Global Antibody Drugs Market 2021

January 2022 | 19 pages | ID: GFE4CC577D74EN
StrategyHelix Inc

Abstracts

An antibody is a protein component of the immune system that circulates in the blood, recognizes foreign substances like bacteria and viruses, and neutralizes them. After exposure to a foreign substance, called an antigen, antibodies continue to circulate in the blood, providing protection against future exposures to that antigen. According to a report by StrategyHelix, the global antibody drugs market is set to increase by US$ 72,340 million during 2021-2027, growing at a CAGR of 9.4% during the forecast period.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for antibody drugs. The global antibody drugs market is segmented on the basis of product, process, diseases, and region. On the basis of product, the global antibody drugs market has been segmented into chimeric mAbs, human mAbs, humanized mAbs, others. Human mAbs was the largest revenue contributor to the global antibody drugs market in 2020 and is anticipated to show the highest growth rate during the forecast period. By process, the global antibody drugs market has been segmented into mammalian cell culture, microbial fermentation. Based on diseases, the global antibody drugs market is categorized into autoimmune diseases, multiple myeloma, lymphoma, and leukemia, solid tumors, others. Geographically, the global antibody drugs market is segmented into Asia Pacific, Europe, North America.

The global antibody drugs market is highly competitive. Key companies profiled in the report include AbbVie Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A.

Report Scope
Product: chimeric mAbs, human mAbs, humanized mAbs, others
Process: mammalian cell culture, microbial fermentation
Diseases: autoimmune diseases, multiple myeloma, lymphoma, and leukemia, solid tumors, others
Region: Asia Pacific, Europe, North America
Years considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the global antibody drugs market
Pinpoint growth sectors and trends for investment

Contents

PART 1. INTRODUCTION

Scope of the study
Study period
Geographical scope
Research methodology

PART 2. ANTIBODY DRUGS MARKET OVERVIEW

PART 3. MARKET BREAKDOWN BY PRODUCT

Chimeric mAbs
Human mAbs
Humanized mAbs
Others

PART 4. MARKET BREAKDOWN BY PROCESS

Mammalian cell culture
Microbial fermentation

PART 5. MARKET BREAKDOWN BY DISEASES

Autoimmune diseases
Multiple myeloma, lymphoma, and leukemia
Solid tumors
Others

PART 6. MARKET BREAKDOWN BY REGION

Asia Pacific
Europe
North America

PART 7. KEY COMPANIES

AbbVie Inc.
Amgen Inc.
AstraZeneca plc
Biogen Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
About StrategyHelix
Disclaimer